Jaguar Health, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (Nasdaq: JAGX) on January 20, 2023, regarding events occurring on that date. The filing details the results of a Special Meeting of Stockholders held on January 20, 2023, and the subsequent implementation of a reverse stock split.
Key Financial Metrics
This filing is a current report regarding corporate governance and capital structure changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
- Reverse Stock Split: The Board of Directors approved a one-for-seventy-five (1-for-75) reverse stock split of the Company's Common Stock. This action was authorized by stockholders at the Special Meeting.
- Effective Date: The reverse stock split became effective at 12:01 a.m. Eastern Time on January 23, 2023.
- Share Reclassification: Every 75 shares of Common Stock issued and outstanding prior to the effective time were automatically reclassified into one share of Common Stock.
- Adjustments: The split proportionally reduced the number of shares issuable upon conversion of non-voting common stock and the exercise of options and warrants, while increasing their respective conversion and exercise prices.
- Fractional Shares: No fractional shares were issued; stockholders entitled to fractional shares received cash payments in lieu thereof.
- Trading: Trading resumed on The Nasdaq Capital Market on a split-adjusted basis on January 23, 2023, under the new CUSIP number 47010C706.
Stockholder Vote Results
Three proposals were submitted to and approved by stockholders at the Special Meeting. As of the record date (November 22, 2022), 151,225,150 shares of Common Stock and 10 shares of Series F Preferred Stock were entitled to vote.
| Proposal | For | Against | Abstained | Broker Non-Votes |
|---|---|---|---|---|
| 1. Reverse Stock Split (1-for-3 to 1-for-75) | 51,789,833,999 | 8,053,911,756 | 237,731,178 | 0 |
| 2. Issuance of Common Stock (20%+ in non-public offering) | 51,998,893 | 8,409,585 | 958,116 | 20,110,339 |
| 3. Adjournment of Special Meeting | 71,451,220 | 8,917,441 | 1,108,272 | 0 |
Outlook and Risks
The filing does not provide specific forward-looking guidance, management commentary on future operations, or a discussion of risks beyond the standard disclosures regarding the reverse stock split mechanics. The primary purpose of the filing is to disclose the material modification to the rights of security holders and the amendment to the Certificate of Incorporation.
Key Facts for Investor Verification
- Verify the new CUSIP number (47010C706) for trading purposes.
- Confirm the adjusted share count and price per share following the 1-for-75 split.
- Review the impact of the split on outstanding options, warrants, and convertible securities.
- Check for cash payments received in lieu of fractional shares if applicable.
- Monitor the Company's compliance with Nasdaq listing requirements post-split.